Testing for minimal residual disease (MRD) is increasingly being used in patients with cancer because deep MRD negativity is associated with better outcomes for patients and MRD status can help make ...
The first and only test authorized by the FDA to detect and monitor minimal residual disease (MRD) in multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL) has received coverage for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results